HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Monopar Therapeutics in a report issued on Wednesday, July 22nd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($1.35) per share for the year, up from their prior forecast of ($1.37). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2028 earnings at $0.91 EPS, FY2029 earnings at $2.41 EPS and FY2030 earnings at $6.61 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41.

A number of other brokerages have also issued reports on MNPR. BTIG Research boosted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday, March 30th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $112.08.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $105.70 on Friday. The stock has a market capitalization of $708.19 million, a P/E ratio of -55.63 and a beta of 1.46. The company has a 50 day moving average price of $79.49 and a 200 day moving average price of $66.36. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $116.64.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its position in Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares during the period. RA Capital Management L.P. increased its position in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after acquiring an additional 156,000 shares during the period. Siren L.L.C. increased its position in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC raised its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at $18,904,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.